Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK574776PMID: 34699155
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 625115-55-1
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of riociguat during breastfeeding. The manufacturer recommends that breastfeeding be avoided during riociguat use. The drug should be absent from breastmilk 3 days after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Riociguat
CAS Registry Number
625115-55-1
Drug Class
Breast Feeding
Lactation
Enzyme Activators
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Review Venetoclax.[Drugs and Lactation Database (...]Review Venetoclax.. Drugs and Lactation Database (LactMed®). 2006
- Review Nilotinib.[Drugs and Lactation Database (...]Review Nilotinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Osimertinib.[Drugs and Lactation Database (...]Review Osimertinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Futibatinib.[Drugs and Lactation Database (...]Review Futibatinib.. Drugs and Lactation Database (LactMed®). 2006
- Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylyl cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine] and YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl Indazole].[J Pharmacol Exp Ther. 2006]Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylyl cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine] and YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl Indazole].Teixeira CE, Priviero FB, Webb RC. J Pharmacol Exp Ther. 2006 Apr; 317(1):258-66. Epub 2005 Dec 13.
- Riociguat - Drugs and Lactation Database (LactMed®)Riociguat - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...